Amgen 'Completely Ignoring' Biosimilar Law, Genentech Says
Amgen Inc. has been "completely ignoring" its information-disclosure obligations under the federal biosimilars law in order to shield its biosimilar of blockbuster cancer drug Avastin, Genentech Inc. claims in a newly...To view the full article, register now.
Already a subscriber? Click here to view full article